此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Gastrointestinal Hormonal Regulation of Obesity

2021年3月10日 更新者:VA Office of Research and Development
The objective of this study is to test and determine whether a high protein diet is efficacious, safe and beneficial to curtail food intake and body weight in obese adult human patients and to establish whether neurohormonal mechanisms of a high protein diet induce an early signal of fullness or satiety in a relevant experimental model, focusing on activation of gastric vagal afferents.

研究概览

详细说明

Obesity is a major cause of morbidity and mortality within the VA medical system accounting for the majority of cases of diabetes mellitus, hypertension, coronary artery disease and cerebrovascular accidents. An improved understanding of the regulation of body weight in Veteran obese patients will improve the quality of life by avoidance of serious medical complications and by suggesting novel therapeutic approaches.

The large proportion of the Veteran population that frequent the VA health care system and who suffer from obesity or have obesity-related illnesses can benefit from this research.

Obesity is associated with early mortality in the United States. It has been estimated to result in about 280,000 deaths per year in U.S. adults and the expenses related to obesity are in excess of $80 billion. Obesity is a major cause of morbidity and mortality within the VA medical system accounting for the majority of cases of diabetes mellitus, hypertension, coronary artery disease and cerebrovascular accidents.

The proposed studies will address important physiological questions regarding the mechanisms of gut peptides regulating satiety and food intake, as well as provide potentially important clinical treatment strategies. The release of GI hormones in response to meal stimuli plays an important role in the regulation of body weight homeostasis. The neural pathways interconnecting gut signaling of satiety to the brain in response to nutrient intake are regulated by neuropeptides and GI hormones.

The investigators have a long history in the study of GI hormones. In the current application, the investigators plan to elucidate the impact of a high protein diet on the profile of gut hormones released postprandially in obese subjects and the underlying changes at the neuronal (vagal afferent) level that take place in response to a high protein diet in a relevant experimental model.

Understanding the regulatory mechanisms involved in satiety will provide clues for existing and novel forms of therapies. Studies may also provide insight into underlying mechanisms responsible for weight loss induced by gastroplasty and bariatric procedure used for the treatment of obesity.

The study design is a three-group randomized, controlled study. This randomized controlled study lasting 24-30 months will assign approximately 198 volunteer subjects (ages 30, BMI 27-40 kg/m2) (66 subjects each) to the following three groups who will adhere to diets with the same number of calories:

  1. Very high protein diet group based on 1.4 gram of protein per pound of lean body mass,
  2. High protein diet group based on 1 gram of protein per pound of lean body mass, and
  3. Standard protein diet group as control based on 0.5 gram protein per pound of lean body mass with same calories.

All participants will meet with a Registered Dietitian (who it is anticipated will join the research study team), to assist them with their diet efforts in all the arms.

In the study, the percent energy from fat will be held constant at 30% and the differences in the diets relate only to the protein and carbohydrate contents (35% protein and 35% carbohydrate, 25% protein and 45% carbohydrate, and 12.5% protein and 57.5% carbohydrate respectively).

We will assess the efficacy of a high protein diet on satiety and pattern of postprandial gut hormone in obese patients. All the subjects will be followed by a dietitian and determination of circulating gut hormone and biochemical assays will be performed.

研究类型

介入性

注册 (实际的)

31

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • West Los Angeles、California、美国、90073
        • VA Greater Los Angeles Healthcare System, West Los Angeles, CA

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

30年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

For inclusion in the study, patients must fulfill all of the following criteria:

  • Subjects must be able to attend all 7 scheduled study visits at the West LA GI clinic at the VAGLAHS, not including the screening visit.
  • Subjects must sign the VA Greater Los Angeles Healthcare System Institutional Review Board approved written informed consent prior to the initiation of any study-related activities or study specific procedures or randomization.
  • Subjects must have given written authorization for the release of protected health information in compliance with Health Insurance Portability and Accountability Act (HIPAA) regulations.

After the Informed Consent process, these additional Inclusion Criteria will be applied to potential subjects:

  • Age 30 years and older at screening.
  • BMI of 27 to 40 kg/m2 inclusive.
  • Subjects must be in good health as determined by medical history, physical examination performed by the Investigator (Study doctor) at the Screening stage, and screening clinical laboratory tests including chemistry panel and CBC.
  • Must have stable smoking habits (or be non-smokers) for at least 6 months prior to screening and agree not to intend to change such habits during the course of the study.
  • Subjects requiring the regular use of any prescription medication may be admitted to the study, providing the dose is stable.
  • Subjects must be able to communicate and cooperate with the Principal Investigator and the staff and willing to comply with the study instructions.

Exclusion Criteria:

  • Weight instability: Subjects reporting weight change of greater than 3.0 kg in the month prior to screening.
  • Any subject who has been on a very low calorie diet (less than 800 kcal/day) for a period of 4 months or more in the 12 months prior to screening, or who has lost greater than 10 kg in the 6 months prior to screening.
  • Any subject who has a history of diabetic gastroparesis or gastric emptying disorder as indicated in the potential subject's medical history and VA's Computer Patient Record System (CPRS).
  • Use of any other investigational drug(s) within 8 weeks prior to screening.
  • Subjects should not have received antibiotics within the prior 4 weeks of screening.
  • Abnormal laboratory parameters:
  • Serum creatinine greater than 1.6 mg/dL;
  • Liver function tests, alanine transaminase (ALT), alanine transaminase (AST), Bilirubin results greater than 2.0 times the upper limit of normal;
  • Triglycerides greater than 500 mg/dL;
  • Total cholesterol greater than 350 mg/dL;
  • Thyroid-stimulating hormone (TSH) outside of normal range disorder, as indicated in the potential subject's medical history, the VA's Computer Patient Record System (CPRS) and laboratory tests performed during the screening process.
  • Subjects who drink more than 1 alcoholic beverage per day (that is: 1 beer; or 1 glass of wine; or 1 shot of liquor).
  • Pregnant women or women likely to become pregnant during the course of the study may not participate in this study. Female subjects must not be able to conceive by reason of surgery, radiation, one year past the onset of menopause, or an approved method of contraception.
  • No vulnerable subjects will be included in the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:标准饮食
标准蛋白质饮食组作为对照,基于每磅去脂体重 0.5 克蛋白质,具有相同的热量:15% 蛋白质和 55% 碳水化合物。
标准蛋白质饮食作为对照,基于每磅瘦体重 0.5 克蛋白质,等热量(相同数量的卡路里)并且由 15% 的蛋白质和 55% 的碳水化合物组成。
其他名称:
  • 标准蛋白质饮食
有源比较器:高蛋白饮食
高蛋白饮食组基于每磅去脂体重 1 克蛋白质:30% 蛋白质和 40% 碳水化合物。
高水平蛋白质饮食,基于每磅受试者瘦体重含 1 克蛋白质,等热量(相同数量的卡路里)且由 30% 的蛋白质和 40% 的碳水化合物组成。
其他名称:
  • 高蛋白饮食

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Body Weight From Baseline to 12 Months
大体时间:The primary outcome of weight loss is measured at the Baseline at Day 1, and at the end of the 12 months study period for each subject.
The primary objective is to compare weight loss between each of the two diets, a high-protein diet versus a standard diet.
The primary outcome of weight loss is measured at the Baseline at Day 1, and at the end of the 12 months study period for each subject.

次要结果测量

结果测量
措施说明
大体时间
Efficacy Variables: Nutrition Assessments (FFQ, 3DFR, and Satiety Questionnaire), Anthropometric Profiles (e.g., Waist and Hip Circumferences), Lab and Biochemical Variables (e.g., Insulin, Lipid Levels, HbA1c), Body Composition (Body Fat), Hormone Level
大体时间:The outcome of efficacy is measured at Day 1 Baseline and at monthly visits during the 12 month study period for each subject.
High-protein diet promotes sensitivity to cholecystokinin and shifts the cecal microbiome without altering brain inflammation in diet-induced obesity
The outcome of efficacy is measured at Day 1 Baseline and at monthly visits during the 12 month study period for each subject.
Safety Variables: Incidence, Severity and Duration of Adverse Events, Vital Signs, Concomitant Medications and Physical Examination Results.
大体时间:Safety variables are measured at the time any adverse events occur, and vital signs, concomitant medications and physical examination results are measured at Baseline on Day 1 and monthly throughout the 12 month study period for each subject.
High-protein diet promotes sensitivity to cholecystokinin and shifts the cecal microbiome without altering brain inflammation in diet-induced obesity
Safety variables are measured at the time any adverse events occur, and vital signs, concomitant medications and physical examination results are measured at Baseline on Day 1 and monthly throughout the 12 month study period for each subject.
Improvement in NAFLD Fibrosis Score
大体时间:1 year
Patients enrolled with a history of NAFLD will be assessed for improvement in NAFLD Fibrosis scoring index and other imaging parameters if performed as standard clinical care.
1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Joseph R Pisegna, MD、VA Greater Los Angeles Healthcare System, West Los Angeles, CA

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2010年9月1日

初级完成 (实际的)

2018年12月31日

研究完成 (实际的)

2019年2月27日

研究注册日期

首次提交

2010年4月2日

首先提交符合 QC 标准的

2010年6月16日

首次发布 (估计)

2010年6月17日

研究记录更新

最后更新发布 (实际的)

2021年4月8日

上次提交的符合 QC 标准的更新

2021年3月10日

最后验证

2021年3月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • F7219-R

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

在美国制造并从美国出口的产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅